Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Joel Cutler Biography and Net Worth

Director of Warby Parker

Joel Cutler has served as a member of our board of directors since 2012. Since January 2000, Mr. Cutler has served as a Co-Founder and Managing Director at General Catalyst Partners, a venture capital firm. Mr. Cutler serves on the board of directors of Oscar Health, Inc. and Lemonade, Inc., and on the board of private companies Lola Travel Company, Inc., Zego Inc., Multiverse Group Ltd, Well Dot, Inc., SESAME, Inc., Empathy.co, and Bloomscape, Inc. Mr. Cutler also serves on several nonprofit organizations’ board of directors, including Warby Parker Impact Foundation, Boston Children’s Hospital Trust, and Beth Israel Deaconess Medical Center. Mr. Cutler holds a Bachelor of Arts degree from Colby College and a Juris Doctor degree from Boston College Law School.

What is Joel E. Cutler's net worth?: The estimated net worth of Joel E. Cutler is at least $137,707.40 as of January 19th, 2021. Mr. Cutler owns 11,428 shares of Warby Parker stock worth more than $137,707 as of April 19th. This net worth evaluation does not reflect any other assets that Mr. Cutler may own. Learn More about Joel E. Cutler's net worth.
How do I contact Joel E. Cutler?: The corporate mailing address for Mr. Cutler and other Warby Parker executives is 233 SPRING STREET 6TH FLOOR EAST, NEW YORK NY, 10013. Warby Parker can also be reached via phone at 646-847-7215 and via email at [email protected]. Learn More on Joel E. Cutler's contact information.
Has Joel E. Cutler been buying or selling shares of Warby Parker?: Joel E. Cutler has not been actively trading shares of Warby Parker during the past quarter. Most recently, Joel E. Cutler sold 13,667 shares of the business's stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $43.07, for a transaction totalling $588,637.69. Learn More on Joel E. Cutler's trading history.
Who are Warby Parker's active insiders?: Warby Parker's insider roster includes Neil Blumenthal (CEO), Joel Cutler (Director), and Steven Miller (CFO). Learn More on Warby Parker's active insiders.
Are insiders buying or selling shares of Warby Parker?: During the last year, insiders at the sold shares 19 times. They sold a total of 974,537 shares worth more than $11,706,554.67. The most recent insider tranaction occured on March, 8th when CEO David Abraham Gilboa sold 52,065 shares worth more than $635,193.00. Insiders at Warby Parker own 26.9% of the company. Learn More about insider trades at Warby Parker.
Information on this page was last updated on 3/8/2024.

Joel E. Cutler Insider Trading History at Warby Parker

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
12/15/2021	Sell	13,667	$43.07	$588,637.69
12/13/2021	Sell	137,000	$45.74	$6,266,380.00
12/10/2021	Sell	127,000	$46.56	$5,913,120.00

Joel E. Cutler Buying and Selling Activity at Warby Parker

Warby Parker Company Overview

Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York.

Today's Range

Now: $12.05

$11.77

$12.25

50 Day Range

MA: $13.09

$11.46

$15.04

2 Week Range

Now: $12.05

$9.83

$16.49

Volume

1,008,738 shs

Average Volume

1,203,551 shs

Market Capitalization

$1.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

Tiny Biotech Stock Wins $75 Billion Patent

From Behind the Markets | Ad

Find out more here >>>